创新CMV预防药来特莫韦儿童适应证在华获批

Core Insights - Merck's new non-nucleoside CMV inhibitor, Prevymis® (Letermovir), has been approved by the NMPA in China for use in children aged 6 months and older weighing ≥6kg, marking a significant advancement in CMV prevention for HSCT patients [1][2] - Prevymis® is the first and only CMV prevention option available in China for both adult and pediatric HSCT recipients, providing a new choice for infection control in this vulnerable population [1] Group 1 - Prevymis® (Letermovir) has received approval for use in pediatric patients, expanding its application beyond adult patients since its initial approval in 2022 [2] - The approval is expected to have a positive and profound impact on the CMV prevention model in HSCT, offering hope to children suffering from malignant blood diseases [2] Group 2 - CMV is a widespread herpes virus that poses a serious threat to the health of HSCT patients, with studies indicating that CMV infections can increase transplant-related mortality rates [1] - In China, the seroprevalence of CMV infection in infants and young children is notably high, ranging from 60% to 80%, highlighting the importance of effective prevention strategies [1]